Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorNational Taiwan University Hospital
About this trial
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
adult gastric cancer receiving gastrectomy
Disqualifiers
Hepatic insufficiency
Renal insufficiency
can not tolerate oral or enteral feeding 7 days after gastrectomy
can not receive computed tomograph
Trial design
Design model
Parallel
Treatments tested in this trial
oral glutamine
Dietary supplement10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
Maltodextrin
Dietary supplementMaltodextrin
Treatment groups
120 Participants
are divided into 2 treatment groupsGroup A: Without oral glutamine supplementationPlacebo comparator 1 intervention
Group B: With oral glutamine supplementationActive comparator 2 interventions
Trial outcomes
Primary outcomes
1
Change of area of psoas muscle
area od psoas muscle on the CT scan
Time frame
84 days after gastrectomySecondary outcomes
1
Walking steps
the average daily walking steps recorded by the wearable devices
Time frame
28,56, and 84 days after gastrectomy2
body weight
body weight
Time frame
84 days after gastrectomy3
Change of serum albumin value
Time frame
84 days after gastrectomy4
Change in white blood cells counts
Time frame
84 days after gastrectomySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov